Clinical outcome and toxicity evaluation of simultaneous integrated boost pelvic IMRT/VMAT at different dose levels combined with androgen deprivation therapy in prostate cancer patients

The role of dose escalation in patients receiving long-term androgen deprivation therapy is still a controversial issue. The aim of the current study was to evaluate whether dose escalation for ≥76–80 Gy had any advantage in terms of biochemical disease-free survival, distant metastasis-free survival, or overall survival outcomes over the dose levels from 70 to <76 Gy.
Dove Medical Press